Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Changes in the Board of Directors

12/03/2021 | 11:40am EST

Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022.

Mr Paul Bulcke, who has been serving on the Board of Directors since 2011, has decided not to stand for re-election at the AGM in 2022, following almost eleven years of tenure. The Board of Directors proposes Dr Jemilah Mahmood, currently the Special Advisor on Public Health to Malaysia’s prime minister, for election to the Board of Directors at the AGM 2022.

“As a member of the Board and of the Audit Committee, Paul Bulcke has made significant contributions to Roche’s success,” said Roche Chairman Christoph Franz. “On behalf of the Board of Directors, I would like to extend our sincere thanks to Paul Bulcke who gave great support to Roche with his enormous leadership experience and his strong entrepreneurial thinking.” Christoph Franz added: “I am delighted with our nomination of Jemilah Mahmood for election as a new member of the Board. Jemilah Mahmood brings a wealth of experience in public health and she has profound knowledge of the global challenges and opportunities for better healthcare for people, especially in less developed regions of the world. With this expertise, she can help make our medicines and diagnostics accessible to even more people worldwide.”

The following current members of the Board of Directors are recommended for re-election:

NameBoard member since
Dr Christoph Franz (as Chairman)2011
André Hoffmann1996
Julie Brown2016
Professor Dr Hans Clevers2019
Dr Jörg Duschmalé2020
Dr Patrick Frost2020
Anita Hauser2017
Professor Dr Richard P. Lifton2015
Bernard Poussot2015
Dr Severin Schwan2013
Dr Claudia Süssmuth Dyckerhoff2016

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the thirteenth consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Sileia Urech
Phone: +41 79 935 81 48
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05


© OMX, source GlobeNewswire - EU Press Releases

All news about ROCHE HOLDING AG
01/13ROCHE HOLDINGS AG : JP Morgan gives a Neutral rating
01/12Biogen shares slide as Medicare proposal restricts coverage of Alzheimer's treatments
01/12Oncolytics Biotech Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
01/12Roche launches the cobas« pulse system, an industry first professional blood glucose ma..
01/12Roche Launches Cobas Pulse System
01/11U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patients
01/11Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional ..
01/11SyroSyros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Ful..
01/11ROCHE HOLDINGS AG : Deutsche Bank reiterates its Buy rating
01/11Roche introduces cobas infinity edge, a new open digital ecosystem for point of care pr..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2021 62 383 M 68 222 M 68 222 M
Net income 2021 15 276 M 16 706 M 16 706 M
Net Debt 2021 6 241 M 6 826 M 6 826 M
P/E ratio 2021 19,9x
Yield 2021 2,72%
Capitalization 296 B 324 B 323 B
EV / Sales 2021 4,84x
EV / Sales 2022 4,78x
Nbr of Employees 101 465
Free-Float -
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 365,00 CHF
Average target price 403,88 CHF
Spread / Average Target 10,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-3.72%323 901
JOHNSON & JOHNSON-1.35%441 855
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%218 444